You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 15, 2024

Claims for Patent: 9,643,929

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,643,929

Title:	Asymmetric catalytic reduction of oxcarbazepine
Abstract:	A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00001## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, R.sup.1 can be the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NR.sup.3R.sup.4R.sup.5 and formic acid, [R.sup.3R.sup.4R.sup.5NH][OOCH] and optionally formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.
Inventor(s):	Learmonth; David Alexander (Alfena, PT), Grasa; Gabriela Alexandra (Mantua, NJ), Zanotti-Gerosa; Antonio (Cambridge, GB)
Assignee:	BIAL--PORTELA & CA, S.A. (S. Mamede do Coronado, PT)
Application Number:	14/944,546
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,643,929
Patent Claims:	1. A pharmaceutical composition comprising (S)-(-)-10-acetoxy-10, 11-dihydro-5H-dibenz/b,f/azepin-5-carboxamide having a chemical purity of at least about 99.96%. 2. A pharmaceutical composition comprising an active pharmaceutical ingredient consisting of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepin-5-carboxamide having a chemical purity of at least about 99.96%. 3. The composition of claim 2, wherein the amount of (R)-isomer of (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepin-5-carboxamide is below the limit of detection.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.